DSIP

Research summary

DSIP (Delta Sleep-Inducing Peptide) is a short neuropeptide first isolated from rabbit brain in the 1970s during research into the neurochemistry of slow-wave sleep, and has since been studied as a possible modulator of sleep architecture, stress hormones, and pain signaling.

The published human evidence is small-scale, dated, and genuinely mixed. A few early trials reported modest improvements in sleep continuity, but several double-blind, placebo-controlled studies found the effects were weak or statistically inseparable from placebo, with one concluding short-term treatment was unlikely to offer major benefit for chronic insomnia. No large modern randomized trial has confirmed a reliable effect, and DSIP has never been approved for any medical indication.

Sources: Schneider-Helmert, PubMed 3622582; PubMed 3583493; PubMed 1299794; PubMed 7028502. Findings from published research —not a claim about this product, and not evidence of safety or effectiveness for human use.